Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Appendix
Available only for authorised users
Literature
1.
Cook JA et al (2018) DELTA(2) guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ 363:k3750CrossRef
2.
Scales DC, Rubenfeld GD (2005) Estimating sample size in critical care clinical trials. J Crit Care 20(1):6–11CrossRef
3.
Stanski NL, Wong HR (2020) Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol 16(1):20–31CrossRef
4.
Evans L et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181–1247CrossRef
5.
Cohen J et al (2015) Sepsis: a roadmap for future research. Lancet Infect Dis 15(5):581–614CrossRef
Metadata
Title
Characterizing systematic challenges in sample size determination for sepsis trials
Authors
Alexandre Tran
Shannon M. Fernando
Bram Rochwerg
Christopher W. Seymour
Deborah J. Cook
Publication date
12-04-2022
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 6/2022
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-022-06691-4

Other articles of this Issue 6/2022

Intensive Care Medicine 6/2022 Go to the issue

Correspondence

Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis

Lasting Legacy In Intensive Care Medicine

Oxygen targets

Correction

Correction to: Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study

Correspondence

What about permissive acidosis?

Correspondence

Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply

Narrative Review

Management of moderate to severe traumatic brain injury: an update for the intensivist